What it changes

1 change to S.Amdt. 2360

Adds a section
  1. Adds SEC. __. EXPANDING AND CLARIFYING THE EXCLUSION FOR ORPHAN DRUGS UNDER THE DRUG PRICE NEGOTIATION PROGRAM at the appropriate place in title VII

    Adds a section

    Inserted: SEC. __. EXPANDING AND CLARIFYING THE EXCLUSION FOR ORPHAN DRUGS UNDER THE DRUG PRICE NEGOTIATION PROGRAM.

    Inserted: Section 1192(e) of the Social Security Act (42 U.S.C. 1320f-1(e)) is amended--

    Inserted: (1) in paragraph (1), by adding at the end the following new subparagraph:

    Inserted: "(C) Treatment of former orphan drugs.--In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A)."; and

    Inserted: (2) in paragraph (3)(A)--

    Inserted: (A) by striking "only one rare disease or condition" and inserting "one or more rare diseases or conditions"; and

    Inserted: (B) by striking "such disease or condition" and inserting "one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act)".

    The amendment doesn't say where this goes; the clerk decides.

    Original wording

    At the appropriate place in title VII, insert the following:

Read automatically from the Congressional Record. Check the original before relying on it.

As printed

SA 2617. Mr. BARRASSO submitted an amendment intended to be proposed to amendment SA 2360 proposed by Mr. Thune (for Mr. Graham) to the bill H.R. 1, to provide for reconciliation pursuant to title II of H. Con. Res. 14; which was ordered to lie on the table; as follows:

At the appropriate place in title VII, insert the following:

SEC. __. EXPANDING AND CLARIFYING THE EXCLUSION FOR ORPHAN DRUGS UNDER THE DRUG PRICE NEGOTIATION PROGRAM.

Section 1192(e) of the Social Security Act (42 U.S.C. 1320f-1(e)) is amended--

(1) in paragraph (1), by adding at the end the following new subparagraph:

“(C) Treatment of former orphan drugs.--In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).”; and

(2) in paragraph (3)(A)--

(A) by striking “only one rare disease or condition” and inserting “one or more rare diseases or conditions”; and

(B) by striking “such disease or condition” and inserting “one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act)”.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

Floor Latest Action

Senate amendment submitted

June 29, 2025